Genetic Polymorphisms Affecting Tacrolimus Metabolism and the Relationship to Post-Transplant Outcomes in Kidney Transplant Recipients

References

• Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int. 2010;77(4):299–311. doi:10.1038/ki.2009.377
   PubMed Web of Science ®Google Scholar
• Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43(10):623–653. doi:10.2165/00003088-200443100-00001
   PubMed Web of Science ®Google Scholar
• Degraeve AL, Moudio S, Haufroid V, et al. Predictors of tacrolimus pharmacokinetic variability: current evidences and future perspectives. Expert Opin Drug Metab Toxicol. 2020;16(9):769–782. doi:10.1080/17425255.2020.1803277
   PubMed Web of Science ®Google Scholar
• Tron C, Lemaitre F, Verstuyft C, Petitcollin A, Verdier MC, Bellissant E. Pharmacogenetics of membrane transporters of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2019;58(5):593–613. doi:10.1007/s40262-018-0717-7
   PubMed Web of Science ®Google Scholar
• Zhang X, Lin G, Tan L, Li J. Current progress of tacrolimus dosing in solid organ transplant recipients: pharmacogenetic considerations. Biomed Pharmacother. 2018;102:107–114. doi:10.1016/j.biopha.2018.03.054
   PubMed Web of Science ®Google Scholar
• Komine N, Satoh S, Saito M, et al. Influence of CYP3A5 genetic differences in tacrolimus on quantitative interstitial fibrosis and long-term graft function in kidney transplant recipients. Int Immunopharmacol. 2018;58:57–63. doi:10.1016/j.intimp.2018.03.004
   Web of Science ®Google Scholar
• Anutrakulchai S, Pongskul C, Kritmetapak K, Limwattananon C, Vannaprasaht S. Therapeutic concentration achievement and allograft survival comparing usage of conventional tacrolimus doses and CYP3A5 genotype-guided doses in renal transplantation patients. Br J Clin Pharmacol. 2019;85(9):1964–1973. doi:10.1111/bcp.13980
   Web of Science ®Google Scholar
• Miura M, Satoh S, Kagaya H, et al. Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients. Pharmacogenomics. 2011;12(7):977–984. doi:10.2217/pgs.11.33
   PubMed Web of Science ®Google Scholar
• Zuo XC, Ng CM, Barrett JS, et al. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis. Pharmacogenet Genomics. 2013;23(5):251–261. doi:10.1097/FPC.0b013e32835fcbb6
   PubMed Web of Science ®Google Scholar
• Furuse M, Hosomi S, Nishida Y, et al. The impact of cytochrome P450 3A genetic polymorphisms on tacrolimus pharmacokinetics in ulcerative colitis patients. PLoS One. 2021;16(4):e0250597. doi:10.1371/journal.pone.0250597
   PubMed Web of Science ®Google Scholar
• Birdwell KA, Decker B, Barbarino JM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther. 2015;98(1):19–24. doi:10.1002/cpt.113
   PubMed Web of Science ®Google Scholar
• Elens L, Capron A, van Schaik RH, et al. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines. Ther Drug Monit. 2013;35(5):608–616. doi:10.1097/FTD.0b013e318296045b
   PubMed Web of Science ®Google Scholar
• Lunde I, Bremer S, Midtvedt K, et al. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. Eur J Clin Pharmacol. 2014;70(6):685–693. doi:10.1007/s00228-014-1656-3
   PubMed Web of Science ®Google Scholar
• Bouamar R, Shuker N, Hesselink DA, et al. Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials(†). Am J Transplant. 2013;13(5):1253–1261. doi:10.1111/ajt.12191
   PubMed Web of Science ®Google Scholar
• Taber DJ, Gebregziabher MG, Srinivas TR, Chavin KD, Baliga PK, Egede LE. African-American race modifies the influence of tacrolimus concentrations on acute rejection and toxicity in kidney transplant recipients. Pharmacotherapy. 2015;35(6):569–577. doi:10.1002/phar.1591
   PubMed Web of Science ®Google Scholar
• Rojas L, Neumann I, Herrero MJ, et al. Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies. Pharmacogenomics J. 2015;15(1):38–48. doi:10.1038/tpj.2014.38
   PubMed Web of Science ®Google Scholar
• Thervet E, Loriot MA, Barbier S, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther. 2010;87(6):721–726. doi:10.1038/clpt.2010.17
   PubMed Web of Science ®Google Scholar
• Shuker N, Bouamar R, van Schaik RH, et al. A randomized controlled trial comparing the efficacy of Cyp3a5 genotype-based with body-weight-based tacrolimus dosing after living donor kidney transplantation. Am J Transplant. 2016;16(7):2085–2096. doi:10.1111/ajt.13691
   PubMed Web of Science ®Google Scholar
• Summers DM, Watson CJ, Pettigrew GJ, et al. Kidney donation after circulatory death (DCD): state of the art. Kidney Int. 2015;88(2):241–249. doi:10.1038/ki.2015.88
   PubMed Web of Science ®Google Scholar
• van Gelder T, Meziyerh S, Swen JJ, de Vries APJ, Moes D. The clinical impact of the C(0)/D ratio and the CYP3A5 genotype on outcome in tacrolimus treated kidney transplant recipients. Front Pharmacol. 2020;11:1142. doi:10.3389/fphar.2020.01142
   PubMed Web of Science ®Google Scholar
• Hannachi I, Ben Fredj N, Chadli Z, et al. Effect of CYP3A4*22 and CYP3A4*1B but not CYP3A5*3 polymorphisms on tacrolimus pharmacokinetic model in Tunisian kidney transplant. Toxicol Appl Pharmacol. 2020;396:115000. doi:10.1016/j.taap.2020.115000
   PubMed Web of Science ®Google Scholar
• Cusinato DA, Lacchini R, Romao EA, Moysés-Neto M, Coelho EB. Relationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patients. Br J Clin Pharmacol. 2014;78(2):364–372. doi:10.1111/bcp.12345
   Web of Science ®Google Scholar
• Pulk RA, Schladt DS, Oetting WS, et al. Multigene predictors of tacrolimus exposure in kidney transplant recipients. Pharmacogenomics. 2015;16(8):841–854. doi:10.2217/pgs.15.42
   Web of Science ®Google Scholar
• Li JL, Liu S, Fu Q, et al. Interactive effects of CYP3A4, CYP3A5, MDR1 and NR1I2 polymorphisms on tacrolimus trough concentrations in early postrenal transplant recipients. Pharmacogenomics. 2015;16(12):1355–1365. doi:10.2217/pgs.15.78
   PubMed Web of Science ®Google Scholar
• Oetting WS, Wu B, Schladt DP, et al. Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients. Pharmacogenomics. 2018;19(3):175–184. doi:10.2217/pgs-2017-0187
   Web of Science ®Google Scholar
• Genvigir FDV, Nishikawa AM, Felipe CR, et al. Influence of ABCC2, CYP2C8, and CYP2J2 polymorphisms on tacrolimus and mycophenolate sodium-based treatment in Brazilian kidney transplant recipients. Pharmacotherapy. 2017;37(5):535–545. doi:10.1002/phar.1928
   PubMed Web of Science ®Google Scholar
• Jannot AS, Vuillemin X, Etienne I, et al. A lack of significant effect of POR*28 allelic variant on tacrolimus exposure in kidney transplant recipients. Ther Drug Monit. 2016;38(2):223–229. doi:10.1097/FTD.0000000000000267
   PubMed Web of Science ®Google Scholar
• Stifft F, van Kuijk SMJ, Bekers O, Christiaans MHL. Increase in tacrolimus exposure after steroid tapering is influenced by CYP3A5 and pregnane X receptor genetic polymorphisms in renal transplant recipients. Nephrol Dial Transplant. 2018;33(9):1668–1675. doi:10.1093/ndt/gfy096
   Web of Science ®Google Scholar
• Knops N, Levtchenko E, van den Heuvel B, Kuypers D. From gut to kidney: transporting and metabolizing calcineurin-inhibitors in solid organ transplantation. Int J Pharm. 2013;452(1–2):14–35. doi:10.1016/j.ijpharm.2013.05.033
   Web of Science ®Google Scholar
• Spallanzani V, Bindi L, Bianco I, et al. Red blood cell exchange as an approach for treating a case of severe tacrolimus overexposure. Transfus Apher Sci. 2017;56(2):238–240. doi:10.1016/j.transci.2017.01.004
   Web of Science ®Google Scholar
• Brown NW, Gonde CE, Adams JE, Tredger JM. Low hematocrit and serum albumin concentrations underlie the overestimation of tacrolimus concentrations by microparticle enzyme immunoassay versus liquid chromatography-tandem mass spectrometry. Clin Chem. 2005;51(3):586–592.
   Web of Science ®Google Scholar
• Stratta P, Quaglia M, Cena T, et al. The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation. Eur J Clin Pharmacol. 2012;68(5):671–680. doi:10.1007/s00228-011-1150-0
   Web of Science ®Google Scholar
• Zahir H, McCaughan G, Gleeson M, Nand RA, McLachlan AJ. Factors affecting variability in distribution of tacrolimus in liver transplant recipients. Br J Clin Pharmacol. 2004;57(3):298–309. doi:10.1046/j.1365-2125.2003.02008.x
   PubMed Web of Science ®Google Scholar
• Chow FS, Piekoszewski W, Jusko WJ. Effect of hematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion. Drug Metab Dispos. 1997;25(5):610–616.
   PubMed Web of Science ®Google Scholar
• Anglicheau D, Flamant M, Schlageter MH, et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant. 2003;18(11):2409–2414. doi:10.1093/ndt/gfg381
   PubMed Web of Science ®Google Scholar
• Vanhove T, Bouwsma H, Hilbrands L, et al. Determinants of the magnitude of interaction between tacrolimus and voriconazole/posaconazole in solid organ recipients. Am J Transplant. 2017;17(9):2372–2380. doi:10.1111/ajt.14232
   PubMed Web of Science ®Google Scholar
• Chen X, Wang DD, Xu H, Li ZP. Initial dosage optimization of tacrolimus in Chinese pediatric patients undergoing kidney transplantation based on population pharmacokinetics and pharmacogenetics. Expert Rev Clin Pharmacol. 2020;13(5):553–561. doi:10.1080/17512433.2020.1767592
   PubMed Web of Science ®Google Scholar
• Chen X, Wang D, Xu H, Li Z. Initial dose optimization of tacrolimus for children with systemic lupus erythematosus based on the CYP3A5 polymorphism and coadministration with Wuzhi capsule. J Clin Pharm Ther. 2020;45(2):309–317.
   PubMed Web of Science ®Google Scholar
• Yan L, Yang ZQ, Shi YY, et al. Effects of wuzhi capsules on blood concentration of tacrolimus in renal transplant recipients. Ann Transplant. 2019;24:594–604. doi:10.12659/AOT.918980
   PubMed Web of Science ®Google Scholar
• Cheng F, Li Q, Wang J, Zeng F, Zhang Y. Effects and safety evaluation of wuzhi capsules combined with tacrolimus for the treatment of kidney transplantation recipients. J Clin Pharm Ther. 2021;46(6):1636–1649. doi:10.1111/jcpt.13493
   PubMed Web of Science ®Google Scholar
• Vandenbussche C, Van der Hauwaert C, Dewaeles E, et al. Tacrolimus-induced nephrotoxicity in mice is associated with microRNA deregulation. Arch Toxicol. 2018;92(4):1539–1550. doi:10.1007/s00204-018-2158-3
   PubMed Web of Science ®Google Scholar
• Mittal N, Thompson JF, Kato T, Tzakis AG. Tacrolimus and diarrhea: pathogenesis of altered metabolism. Pediatr Transplant. 2001;5(2):75–79. doi:10.1034/j.1399-3046.2001.005002075.x
   Web of Science ®Google Scholar
• Hoorn EJ, Walsh SB, McCormick JA, et al. The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nat Med. 2011;17(10):1304–1309. doi:10.1038/nm.2497
   PubMed Web of Science ®Google Scholar
• Davis S, Gralla J, Klem P, et al. Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation. Am J Transplant. 2018;18(4):907–915. doi:10.1111/ajt.14504
   PubMed Web of Science ®Google Scholar
• Borobia AM, Romero I, Jimenez C, et al. Trough tacrolimus concentrations in the first week after kidney transplantation are related to acute rejection. Ther Drug Monit. 2009;31(4):436–442. doi:10.1097/FTD.0b013e3181a8f02a
   PubMed Web of Science ®Google Scholar
• Brunet M, van Gelder T, Åsberg A, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit. 2019;41(3):261–307. doi:10.1097/FTD.0000000000000640
   PubMed Web of Science ®Google Scholar
• Hu R, Barratt DT, Coller JK, Sallustio BC, Somogyi AA. Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation. Pharmacogenet Genomics. 2019;29(1):9–17. doi:10.1097/FPC.0000000000000360
   Web of Science ®Google Scholar
• Xia ZW, Jun CY, Hao C, Bing C, Min SM, Jie XJ. The occurrence of diarrhea not related to the pharmacokinetics of MPA and its metabolites in liver transplant patients. Eur J Clin Pharmacol. 2010;66(7):671–679. doi:10.1007/s00228-010-0833-2
   Web of Science ®Google Scholar
• Campagne O, Mager DE, Brazeau D, Venuto RC, Tornatore KM. The impact of tacrolimus exposure on extrarenal adverse effects in adult renal transplant recipients. Br J Clin Pharmacol. 2019;85(3):516–529. doi:10.1111/bcp.13811
   PubMed Web of Science ®Google Scholar
• Heller T, van Gelder T, Budde K, et al. Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. Am J Transplant. 2007;7(7):1822–1831. doi:10.1111/j.1600-6143.2007.01859.x
   PubMed Web of Science ®Google Scholar
• Lemahieu W, Maes B, Verbeke K, Rutgeerts P, Geboes K, Vanrenterghem Y. Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. Am J Transplant. 2005;5(6):1383–1391. doi:10.1111/j.1600-6143.2005.00844.x
   PubMed Web of Science ®Google Scholar
• van Boekel GA, Aarnoutse RE, van der Heijden JJ, Hoogtanders KE, Hilbrands LB. Effect of mild diarrhea on tacrolimus exposure. Transplantation. 2012;94(7):763–767. doi:10.1097/TP.0b013e3182629e13
   PubMed Web of Science ®Google Scholar
• Hanouneh IA, Feldstein AE, McCullough AJ, et al. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl. 2008;14(9):1287–1293. doi:10.1002/lt.21524
   PubMed Web of Science ®Google Scholar
• Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant. 2010;10(6):1420–1427. doi:10.1111/j.1600-6143.2010.03126.x
   PubMed Web of Science ®Google Scholar